TOMI Environmental Solutions Announces Specialized Service Provider For Healthcare And Mold Remediation
"We are incredibly excited to partner with them as they make strides into the healthcare industry," said Elissa J. (E.J.) Shane, COO of TOMI Environmental Solutions. "Their leadership, which includes a prominent figure in restoration and seasoned personnel, brings unique industry and operating expertise. They have been extensively trained on our technology and are well-prepared to deliver exceptional service."
This new service provider also has a working relationship with Enviro-Mist Inc., a long-standing exclusive partner of TOMI and experts in mold remediation. Enviro-Mist Inc. continues to use SteraMist for mold remediation as well as the decontamination of pharmaceutical and life sciences facilities throughout the West Coast, including a multi-year service contract for a Pfizer facility.
TOMITM Environmental Solutions, Inc.: Innovating for a safer world®
TOMITM Environmental Solutions, Inc. (NASDAQ: TOMZ ) is a global decontamination and infection prevention company, providing environmental solutions for disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BITTM) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BITTM solution utilizes a low percentage hydrogen peroxide as its only active ingredient and uses patented ionized Hydrogen Peroxide (iHPTM) technology in all SteraMist systems to create superior disinfection. TOMI products are designed to service a broad spectrum of use sites, including, but not limited to, hospitals and medical facilities, biosafety labs, pharmaceutical facilities, commercial and office buildings, schools, restaurants, meat and produce processing facilities, and police and fire departments.
For additional information, please visit or contact us at ...
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management's judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to TOMI's products to serve healthcare sectors. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today's date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.
INVESTOR RELATIONS CONTACT:
John Nesbett/Rosalyn Christian
IMS Investor Relations
...


Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research

- New Cryptocurrency Mutuum Finance (MUTM) Raises $15.8M As Phase 6 Reaches 40%
- Bydfi Joins Korea Blockchain Week 2025 (KBW2025): Deepening Web3 Engagement
- Yield Basis Nears Mainnet Launch As Curve DAO Votes On Crvusd Proposal
- 0G Labs Launches Aristotle Mainnet With Largest Day-One Ecosystem For Decentralized AI
- Ethereum-Based Defi Crypto Mutuum Finance (MUTM) Raises Over $16 Million With More Than 720M Tokens Sold
- Fintech's Gender Gap In Focus: Drofa Comms' Women Leading The Way Joins Evolvh3r's She Connects At TOKEN2049
Comments
No comment